SAB BIOTHERAPEUTICS, INC. Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Noncontrolling Interest
SAB BIOTHERAPEUTICS, INC. (SABS) reported Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Noncontrolling Interest of -$546.79 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToNoncontrollingInterest · last filed 2026-05-12
- SAB BIOTHERAPEUTICS, INC. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$546.79K.
- SAB BIOTHERAPEUTICS, INC. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was $98.36K, a 134639.73% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was $87.75K, a 98.66% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was $328.00, a 97.37% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to noncontrolling interest for fiscal 2025 was $185.46K, a 28565.22% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. other comprehensive income (loss), available-for-sale securities, tax, portion attributable to noncontrolling interest for fiscal 2024 was $647.00.
| Period end | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Noncontrolling Interest 3 month | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Noncontrolling Interest 6 month | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Noncontrolling Interest 9 month | Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$546.79K 10-Q · filed 2026-05-12 | -$448.43K derived: sum of 2 quarters · filed 2026-05-12 | -$360.68K derived: sum of 3 quarters · filed 2026-05-12 | -$360.35K derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | $98.36K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $186.11K derived: sum of 2 quarters · filed 2026-03-09 | $186.44K derived: sum of 3 quarters · filed 2026-03-09 | $185.46K 10-K · filed 2026-03-09 |
| 2025-09-30 | $87.75K 10-Q · filed 2025-11-14 | $88.08K derived: sum of 2 quarters · filed 2025-11-14 | $87.10K 10-Q · filed 2025-11-14 | $87.18K derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-06-30 | $328.00 10-Q · filed 2025-08-07 | -$647.00 10-Q · filed 2025-08-07 | -$574.00 derived: sum of 3 quarters · filed 2026-05-12 | $43.60K derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-03-31 | -$975.00 10-Q · filed 2026-05-12 | -$902.00 derived: sum of 2 quarters · filed 2026-05-12 | $43.27K derived: sum of 3 quarters · filed 2026-05-12 | $55.73K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $73.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $44.24K derived: sum of 2 quarters · filed 2026-03-09 | $56.71K derived: sum of 3 quarters · filed 2026-03-09 | $647.00 10-K · filed 2026-03-09 |
| 2024-09-30 | $44.17K 10-Q · filed 2025-11-14 | $56.63K derived: sum of 2 quarters · filed 2025-11-14 | $574.00 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $12.46K 10-Q · filed 2025-08-07 | -$43.60K 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$56.06K 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |